Hookipa Pharma signs US$958 M Deal with Roche to develop HB-700 for KRAS-mutated Cancers
By Amit Kaushik
Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)
Published: 5 Nov-2022
DOI: 10.3833/pdr.v2022.i11.2745 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Hookipa Pharma has announced a collaboration with Roche for the development and commercialisation of HB-700, a new investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS